Home > Healthcare > Pharmaceuticals > Finished Drug Form > Scopolamine Market

Scopolamine Market Share

Report ID: GMI9743
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Scopolamine Market Share

The scopolamine sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Scopolamine Market Companies

Some of the eminent market participants operating in the scopolamine industry include:

Alchem International Pvt. Ltd.
Australian Alkaloids Ltd.
Baxter International Inc.
Caleb Pharmaceuticals, Inc.
Fine Chemicals Corporation
Fresenius SE & Co. KGaA
GSK plc
Ingenus Pharmaceuticals
Mylan N.V.
Myungmoon Pharm. Co., Ltd.
Novartis AG
Perrigo Company plc
Pfizer Inc.
Phytex Australia
Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Scopolamine industry size was USD 419 million in 2023 and will grow at 5.3% CAGR between 2024 and 2032 due to its extensive application in the pharmaceutical sector for treating motion sickness, nausea, and vomiting.

The motion sickness segment in the scopolamine industry recorded USD 203.9 million in 2023, driven by rising prevalence of motion sickness due to increased travel and transportation activities.

North America scopolamine industry will register USD 241.3 million by 2032, attributed to region's advanced healthcare infrastructure, coupled with high healthcare spending.

Alchem International Pvt. Ltd., Australian Alkaloids Ltd., Baxter International Inc., Caleb Pharmaceuticals, Inc., Fine Chemicals Corporation, Fresenius SE & Co. KGaA, GSK plc, Ingenus Pharmaceuticals, and Mylan N.V. among others.